Lytix Biopharma

Lytix Biopharma AS develops novel antimicrobial peptide-based drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. The company uses proprietary and in-depth knowledge of the general lytic peptide pharmacophore to develop synthetic drug-like molecules that retain the positive characteristics of lytic peptides whilst offering excellent stability and low cost of goods.

Lytix Biopharma is a partner in the Centre for Marine Bioactives and Drug Discovery, MabCent-SFI.